This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Intercept Reports Additional Details About FLINT Trial Provided By NIDDK

NEW YORK, Jan. 12, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) today provided additional information regarding the FLINT clinical trial of obeticholic acid (OCA) in nonalcoholic steatohepatitis (NASH), based on a written statement distributed after market close on January 10, 2014 by the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK), a part of the National Institutes of Health.

The NIDDK confirmed in its statement that:
  • Its decision to halt the 72-week therapeutic phase of FLINT was based on interim efficacy results showing that "OCA has a significant beneficial effect on liver damage due to NASH."  
  • As specified in the protocol, a 24-week follow up period is now commencing and all FLINT patients will stop taking OCA or placebo no later than January 20, 2014.  
  • Both the FLINT investigators and patients enrolled in the trial will remain blinded until completion of the follow up phase. All the trial data will then be thoroughly analyzed and the NIDDK anticipates presenting the results in 4Q 2014.  
  • Lipid abnormalities involving increased total cholesterol and LDL and decreased HDL were seen in OCA-treated patients compared to placebo.  
  • Since lipid abnormalities are common in NASH, all of the patients will be followed for the 24-week period to help determine whether lipids return to pre-treatment levels.

While the NIDDK did not provide any information concerning the magnitude of lipid effects, Intercept believes that the reported lipid changes in FLINT patients on OCA will likely be similar to the results previously reported in a clinical trial of OCA in diabetic patients with nonalcoholic fatty liver disease (NAFLD) that were presented at the 2009 meeting of the American Association for the Study of Liver Disease (AASLD) by Dr. Arun Sanyal and subsequently described in a paper published in the journal Gastroenterology in 2013 (Mudaliar et al.).  The efficacy results from this earlier trial (insulin sensitization, weight loss and liver enzyme improvements), together with the safety and tolerability profile of OCA, established the basis for its selection as the therapeutic candidate in FLINT in 2010.

"OCA is an FXR agonist and we have known for a long time that it is involved in many aspects of lipid metabolism," said Mark Pruzanski, M.D., Intercept's Chief Executive Officer. "An important part of the rationale for advancing our drug in NASH is that by activating FXR in the liver, we believe that it reduces the excess lipid load which is a causal factor in the disease. In addition, there is preclinical evidence that by activating FXR systemically, OCA is able to shunt excess lipids away from collecting in arteries and other organs which could also be beneficial. It is in any case clear that the lipid changes seen in OCA-treated patients are part of a complex set of mechanisms and we are already conducting further studies to gain a more complete understanding of the clinical implications."    

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.28 -1.00%
FB $118.48 0.57%
GOOG $706.48 0.72%
TSLA $212.00 0.22%
YHOO $36.82 -0.32%


Chart of I:DJI
DOW 17,638.22 -22.49 -0.13%
S&P 500 2,044.40 -6.23 -0.30%
NASDAQ 4,692.2070 -24.8870 -0.53%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs